NTRK1

(redirected from TrkA)
Also found in: Acronyms, Wikipedia.

NTRK1

A gene on chromosome 1q21-q22 that encodes neurotrophic tyrosine kinase receptor type 1 (TrkA) which, after neurotrophin binding, phosphorylates itself (autophosphorylates) and members of the MAPK pathway. TrkA potently binds nerve growth factor (NGF) and is involved in differentiation and survival of neurons and in control of gene expression of enzymes involved in neurotransmitter synthesis. It is involved in cell differentiation and may play a role in specifying sensory neuron subtypes.

Molecular pathology
NTRK1 mutations are associated with congenital insensitivity to pain with anhidrosis, self-mutilating behaviour, mental retardation and cancer.
References in periodicals archive ?
Notably, NGF activation of TrkA in cultured thecal cells is reported to be involved in the disruption of gap junctions (Mayerhofer, 1996).
Researchers have observed that concurrent exposure to NGF and thimerosal decreased TrkA autophosphorylation (144).
The high-affinity receptor for NGF is the trkA subtype (Kernie and Parada 2000).
Expression of mRNAs for neurotrophic factors (NGF, BDNF, NT-3, and GDNF) and their receptors (p75NGFR, TrkA, TrkB, and TrkC) in the adult human peripheral nervous system and nonneural tissues.
NGF and its receptors, the tyrosine-kinase receptor TrkA and the p75 NTR receptor are responsible for the survival and maintenance of specific subsets of peripheral neurons and basal forebrain cholinergic nuclei during development and maturation.
TrkA is a member of a larger family of important signaling proteins known as tyrosine receptor kinases.
Prestigious peer-review journal accepts paper demonstrating a reduction of pruritus (itch) in psoriasis patients treated with its novel TrkA kinase inhibitor CT327
Among the novel targets are HDAC, TrkA, p38 MAP kinase, PDE-IV, LFA-1, cathepsin-S, adenosine A3 receptor, RAMBA, flt-3, ICAM, selectin and many more.
GBR 900 is a first in class monoclonal antibody for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor (NGF)
CT327 is a novel topical targeted treatment for chronic pruritus in diseases of dermatology, such as psoriasis and atopic dermatitis, targeting the sensory neurones implicated in the disease through the inhibition of TrkA kinase.
Of the 21 IHCs, 15 will be available immediately and include: PD1, PD-L1, MGMT, MET, TOP1, PTEN, AR, CAIX, ER, HER2, IDO, PR, TRKA, TRKB and TUBB3.
CT327 (a TrkA kinase inhibitor) is a novel topical treatment for chronic pruritus in diseases of dermatology such as atopic dermatitis and psoriasis.